

CURRICULUM VITAE ET STUDIORUM OF LUCA PASTORELLI, M.D., Ph.D.

Personal data:

- Born in Tortona (AL), Italy, on November 6th 1977

Education:

- 1996: High School Degree obtaining the maximum score (60/60) at Liceo Scientifico Statale L. Amaldi – Novi Ligure (AL), Italy
- October 18th, 2002: Graduated with a first-class honours degree (110/110 magna cum laude) in Medicine at University of Milan, disserting the thesis: “EcoColor-Doppler accuracy in evaluation of Crohn’s disease activity”
- November 7th, 2006: Completed the residency in Gastroenterology and Digestive Endoscopy, obtaining the maximum score (70/70 magna cum laude) at University of Milan, Milano, disserting the thesis: “Parnaparin for the treatment of left, mild to moderate ulcerative colitis: safety and efficacy of a novel oral, controlled colonic-release formulation (MMX™)”.
- September 6th, 2011: PhD awarded in Medical-surgical Gastroenterological Sciences and Transplants at University of Bologna with the thesis: “Expression and functional role of Interleukin-33 and its receptor, ST2, in inflammatory bowel diseases”.

Academic positions

- November 2006-October 2010 and June 2011-April 2013: Research fellowship at University of Milan, under the mentorship of Prof. Maurizio Vecchi
- Tutor of medical students during their clinical training at University of Milan during the academic years 2009-2010 and 2010-2011
- April 2013-April 2018: Research Fellow, at the Department of Biomedical Sciences for Health, University of Milan, Milan
- Since July 2019: Associate Professor of Gastroenterology, at the Department of Biomedical Sciences for Health, University of Milan, Milan

Clinical experience:

- From November 2002 to November 2006 residency in Gastroenterology and Digestive Endoscopy at the school of specialization in Gastroenterology and Digestive Endoscopy of Milan, University of Milan, Milan, Italy
- January 2011-October 2017: clinical and endoscopic activity as consultant gastroenterologist at Division of Gastroenterology and Gastrointestinal Endoscopy (Director: Prof. Maurizio Vecchi), IRCCS Policlinico San Donato, San Donato Milanese, Italy
- Since November 1st 2017: Head of the Gastroenterology Unit at IRCCS Policlinico San Donato, San Donato Milanese, Italy.

Scientific experience abroad

- September 2004 – October 2004: research and laboratory training under the supervision of Prof. Claudio Fiocchi at the Division of Gastroenterology, University Hospitals of Cleveland, Case Western University, Cleveland, Ohio
- December 2007 – January 2009: Research Associate at Digestive Health Center, Department of Medicine, University of Virginia, Charlottesville, Virginia, working in collaboration with Prof. Theresa T Pizarro
- February 2009 – April 2010: Research Associate at Department of Pathology, Case Western Reserve University, Cleveland, Ohio, working in collaboration with Prof. Theresa T Pizarro

Principal Investigator for the following clinical trials:

1. GO-CARE: "Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis".
2. GA29145: "An open-label extension and safety monitoring study of patients with moderately to severely active crohn's disease previously enrolled in the Etrolizumab phase III protocol GA29144".
3. REDIV/002/17: "Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial".
4. GA28950: "Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Have Been Previously Exposed to TNF Inhibitors".
5. GA28951: "An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies".
6. MLN0002SC-3031: "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy".
7. MLN0002SC-3027: "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy".
8. MLN0002SC-3030: "A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease".
9. CB-01-11/28: "A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel syndrome (IBS-D)".
10. GA29103: "Phase III, randomized, multicenter double-blind, double dummy study to evaluate the efficacy and safety of Etrolizumab compared with Infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors".
11. BUG-3/MIC: "Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis".
12. CSUC-01/16: "A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients".
13. MLN-0002_401: "Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease".
14. CNT01275CRD3005_STARDUST: "Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab".
15. C1231001: "Post-marketing Observational Cohort Study Of Patients With Inflammatory Bowel Disease (Ibd) Treated With Ct-p13 In Usual Clinical Practice (Connect-ibd)".

16. 16T-MC-AMAN: "A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis".
17. 16T-MC-AMBG: "A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study Of Mirikizumab In Patients With Moderately To Severely Active Ulcerative Colitis (Lucent 2)".
18. RETIPC/01/17: "A Phase II, multicentre, double-blind, randomised, placebo-controlled study of Rifaximin delayed release 400 mg tablet: clinical efficacy and safety in the prevention of post-operative endoscopic Crohn's disease recurrence".
19. PSC-DS PROBE2-IBS/17: "L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study".
20. GED-0301-CD-002: "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease".
21. GED-0301-CD-003: "A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease".
22. GED-0301-CD-004: "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease".
23. Vedolizumab-4013: "Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease".
24. GA29144: "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease".
25. 000217_CORE PRACTICE: "A Prospective Multi-centre Observational Cohort Study Assessing the Effectiveness of Cortiment® for the Treatment of Mild-to-moderate Active Ulcerative Colitis in Routine Clinical Practice".
26. LEGAGY: "A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)".

- Last GCP training: January 29th 2019

Society of membership:

- Member, since 2005, of S. I. G. E. (Società Italiana Gastroenterologia); since January 2015 Member of the Steering Committee of S. I. G. E. Lombardia
- Member, since 2005, of A. G. G. E. I. (Associazione Giovani Gastroenterologi ed Endoscopisti Italiani); since February 2015 Member of the Steering Committee of A. G. G. E. I.
- Member, since 2006, of I. G. – I. B. D. (Italian Group for the study of Inflammatory Bowel Disease)
- Full member, since 2008, of A. G. A. (American Gastroenterological Association)
- Since April 2014 Member of the Steering Committee of G. S. M. I. I. (Gruppo Studio Malattie Infiammatorie Intestinali)

Editorial activity:

- Referee for the following journals: "Journal of Crohn's & Colitis", "Inflammatory Bowel Disease", "Digestive & Liver Disease", "Expert Review on Gastroenterology & Hepatology", "Gut Pathogens", "Expert Opinion on Pharmacotherapy", "Frontiers in Medicine", "Current Medicinal Chemistry", "Expert Review of Clinical Pharmacology", "Expert Review on Gastroenterology & Hepatology", "International Archives of

Allergy”, “Traslatational Research”, “United European Gastroenterology Journal”, “World Journal of Gastroenterology” and “Fibrogenesis & Tissue Repair”.

Published scientific papers

1. Pastorelli L, Saibeni S, Spina L, Signorelli C, Celasco G, de Franchis R, Vecchi M. Oral, colonic-release low-molecular-weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. *Aliment Pharmacol Ther* 2008; 28(5): 581-588; on-line ISSN 1365-2036. doi: 10.1111/j.1365-2036.2008.03757.x.
2. Vecchi M, Spina L, Pastorelli L, Cavallaro F, Ciscato C. The relevance of mucosal healing. *Dig Liver Dis Suppl* 2008; 2(1): 9-10.
3. Pastorelli L, Vecchi M, Cominelli F, Pizarro TT. Genetic regulation of epithelial barrier function: Recent insights into the pathogenesis of inflammatory bowel disease. *Inflammatory Bowel Disease Monitor* 2008; 8(4): 124-133; on-line ISSN 2040-3909.
4. Vecchi M, Spina L, Cavallaro F, Pastorelli L. Do antibodies have a role in IBD pathogenesis? *Inflamm Bowel Dis* 2008; 14(S2):S95-S96; on-line ISSN 1536-4844. doi: 10.1002/ibd.20699.
5. Pastorelli L, Pizarro TT, Cominelli F, Vecchi M. Emerging drugs for the treatment of ulcerative colitis. *Expert Opin Emerg Drugs* 2009; 14(3):505-21; on-line ISSN 1744-7623. doi: 10.1517/14728210903146882.
6. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, Fiocchi C, Vecchi M, Pizarro TT. Epithelial-derived IL-33 and its receptor, ST2, are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. *Proc Natl Acad Sci U S A* 2010; 107(17):8017-22; on-line ISSN 1091-6490. doi: 10.1073/pnas.0912678107.
7. Bertomoro P, Renna S, Cottone M, Riegler G, Bossa F, Giglio L, Pastorelli L, Papi C, Castiglione F, Angellucci E, Pica R, Di Paolo MC, D'Inca R. Regional variations in the use of complementary and alternative medicines (CAM) for inflammatory bowel disease patients in Italy: An IG-IBD study. *J Crohns Colitis* 2010; 4(3):291-300; on-line ISSN 1873-9946. doi: 10.1016/j.crohns.2009.12.009.
8. Galliera E, de Girolamo L, Dogliotti G, De Salvo C, Tosetti G, Pastorelli L. Circulating OPG levels are reduced following infliximab treatment and correlate with CRP levels: Is serum OPG a potential marker of IBD disease activity? *Inflamm Bowel Dis* 2011; 17(6):E59-60; on-line ISSN 1536-4844. doi: 10.1002/ibd.21714.
9. Pastorelli L, De Salvo C, Cominelli M, Vecchi M, Pizarro TT. Novel cytokine signaling pathways in IBD: Insights into the dichotomous functions of IL-33 during chronic intestinal inflammation. *Therap Adv Gastroenterol* 2011; 4(5):311-23; on-line ISSN 1756-2848. doi: 10.1177/1756283X11410770.
10. Pizarro TT, Pastorelli L, Bamias G, Garg RR, Reuter BK, Mercado J, Chieppa M, Arsenau K, Ley K, Cominelli F. The SAMP1/YitFc mouse strain: A spontaneous model of Crohn's disease-like ileitis. *Inflamm Bowel Dis* 2011; 17(12):2566-84; on-line ISSN 1536-4844. doi: 10.1002/ibd.
11. Reuter BK, Pastorelli L, Scott KGE, Brogi M, Garg RR, McBride JA, Rowlett RM, Arrieta MC, Wang XM, Keller EJ, Feldman SH, Mize JR, Cominelli F, Meddings JB, Pizarro TT. Spontaneous, immune-mediated gastric inflammation in SAMP1/YitFc mice, a new model of Crohn's-like gastritis. *Gastroenterology* 2011; 141(5):1709-19; on-line ISSN 0016-5085. doi: 10.1053/j.gastro.2011.06.041.
12. Corridoni D, Pastorelli L, Mattioli B, Locovei S, Ishikawa D, Arseneau KO, Chieppa M, Cominelli F, Pizarro TT. Probiotic bacteria regulate intestinal epithelial permeability in experimental ileitis by a TNF-dependent mechanism. *PLoS One* 2012; 7(7):e42067; on-line ISSN 1932-6203. doi: 10.1371/journal.pone.0042067.
13. Latiano A, Palmieri O, Pastorelli L, Vecchi M, Pizarro TT, Bossa F, Merla G, Augello B, Latiano T, Corritore G, Settesoldi A, Valvano MR, D'Inca R, Stronati L, Annese V, Andriulli A. Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. *PLoS One* 2013; 8(4):e62144; on-line ISSN 1932-6203. doi: 10.1371/journal.pone.0062144.
14. Pastorelli L, De Salvo C, Vecchi M, Pizarro TT. The role of IL-33 in gut mucosal inflammation. *Mediators Inflamm* 2013;2013:608187; on-line ISSN 1466-1861. doi: 10.1155/2013/608187.
15. de Nucci G, Pastorelli L, Tontini GE, Spina L, Vecchi M. An update on probiotic therapy for chronic inflammatory bowel diseases in adults. *International Journal of Probiotics & Prebiotics* 2013, 8 (1), 19-23; ISSN 1555-1431.

16. Spina L, Pastorelli L, de Nucci G, Cavallaro F, Tontini GE, Munizio N, Vecchi M. Biologic therapies in Inflammatory Bowel Diseases. *Giornale Italiano di Endoscopia Digestiva* 2013;36(3):179-83; ISSN: 0394-0225.
17. Tontini GE, Spina L, Pastorelli L, de Nucci G, Cavallaro F, Vecchi M, Zanchi C, Martellosi S. Osteoporosi e IBD: il punto di vista del gastroenterologo pediatra e del gastroenterologo dell'adulto. *Giorn Gastr Epatol Nutr Ped* 2013;5(4):22-29.
18. Pastorelli L, De Salvo C, Mercado JR, Vecchi M, Pizarro TT. Central Role of the Gut Epithelial Barrier in the Pathogenesis of Chronic Intestinal Inflammation: Lessons Learned from Animal Models and Human Genetics. *Front Immunol* 2013; 4:280, eCollection 2013; on-line ISSN 1664-3224. doi: 10.3389/fimmu.2013.00280.
19. Tontini GE, Pastorelli L, Spina L, Fabris F, Bruni B, Clemente C, de Nucci G, Cavallaro F, Marconi S, Neurath MF, Neumann H, Tacconi M, Vecchi M. Microscopic colitis and colorectal neoplastic lesion rate in chronic non-bloody diarrhea: a prospective, multicenter study. *Inflamm Bowel Dis* 2014; 20(5):882-91; on-line ISSN 1536-4844. doi: 10.1097/MIB.0000000000000030.
20. Casella G, Tontini GE, Bassotti G, Pastorelli L, Villanacci V, Spina L, Baldini V, Vecchi M. Neurological disorders and inflammatory bowel diseases. *World J Gastroenterol* 2014; 20(27):8764-82; ISSN 1007-9327. doi: 10.3748/wjg.v20.i27.8764.
21. Tontini GE, Cavallaro F, Neumann H, Pastorelli L, Neurath MF, Spina L, Vecchi M. Extensive small-bowel Crohn's disease detected by the newly introduced 360° panoramic viewing capsule endoscopy system. *Endoscopy*. 2014;46 Suppl 1 UCTN:E353-4; ISSN 0013-726X. doi: 10.1055/s-0034-1377358.
22. Tontini GE, Pastorelli L, Spina L. Terapia combinata per la retto-colite ulcerosa di grado lieve e moderato. *Acta Biomedica* 2014;85(QG1):9-10 ISSN 0392-4203.
23. Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: State of the art and future perspectives. *World J Gastroenterol* 2015;21(1):21-46; ISSN 1007-9327. doi: 10.3748/wjg.v21.i1.21.
24. Pastorelli L, Dozio E, Pisani LF, Boscolo-Anzoletti M, Vianello E, Munizio N, Spina L, Tontini GE, Peyvandi F, Corsi Romanelli MM, Vecchi M. Procoagulatory state in inflammatory bowel diseases is promoted by impaired intestinal barrier function. *Gastroenterol Res Pract*. 2015;2015:189341. On-line ISSN: 1687-630X. doi: 10.1155/2015/189341.
25. Tontini GE, Annunziata ML, Cavallaro F, Pastorelli L, Spina L, Vecchi M. Role of endoscopy in inflammatory bowel diseases: Timing and appropriateness. *Giornale Italiano di Endoscopia Digestiva* 2015;38(1):55-9; ISSN: 0394-0225.
26. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP, Lanza DG, Berger NA, Markowitz SD, Lenz HJ, Nadeau JH, Pizarro TT, Heaney JD. IL-33 activates tumor stroma to promote intestinal polyposis. *Proc Natl Acad Sci U S A*. 2015 May 12;112(19):E2487-96. on-line ISSN 1091-6490. doi: 10.1073/pnas.1422445112.
27. Soriani P, Tontini GE, Pastorelli L, Mauri M, Neumann H, Vecchi M, Lagoussis P. Use of an over-the-scope clip for endoscopic sealing of anastomotic dehiscence after anterior resection for rectal cancer. *Endoscopy*. 2015;47 Suppl 1 UCTN:E278-9. ISSN 0013-726X. doi: 10.1055/s-0034-1391875.
28. Tontini GE, Pastorelli L, Ishaq S, Neumann H. Advances in endoscopic imaging in ulcerative colitis. *Expert Rev Gastroenterol Hepatol*. 2015;9(11):1393-405. on-line ISSN: 1747-4132. doi: 10.1586/17474124.2015.1087848.
29. Pisani LF, Tontini GE, Vecchi M, Pastorelli L. Microscopic Colitis: What Do We Know About Pathogenesis? *Inflamm Bowel Dis*. 2016 Feb;22(2):450-8. on-line ISSN 1536-4844. doi: 10.1097/MIB.0000000000000628.
30. Sconfienza LM, Cavallaro F, Colombi V, Pastorelli L, Tontini G, Pescatori L, Esseridou A, Savarino E, Messina C, Casale R, Di Leo G, Sardanelli F, Vecchi M. In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. *Ultrasound Med Biol*. 2016 Apr;42(4):855-63. ISSN: 0301-5629. doi: 10.1016/j.ultrasmedbio.2015.11.023.
31. Lagoussis P, Soriani P, Tontini GE, Neumann H, Pastorelli L, de Nucci G, Vecchi M. Over-the-scope clip-assisted endoscopic full-thickness resection after incomplete resection of rectal adenocarcinoma. *Endoscopy*. 2016;48 Suppl 1:E59-60. ISSN 0013-726X. doi: 10.1055/s-0042-100197.
32. De Salvo C, Wang XM, Pastorelli L, Mattioli B, Omenetti S, Buela KA, Chowdhry S, Garg RR, Goodman WA, Rodriguez-Palacios A, Smith DE, Abbott DW, Cominelli F, Bamias G, Xin W, Lee JJ, Vecchi M, Pizarro TT. IL-33 Drives Eosinophil Infiltration and Pathogenic Type 2 Helper T-Cell Immune Responses Leading to Chronic Experimental Ileitis. *Am J Pathol*. 2016 Apr;186(4):885-98. ISSN: 0002-9440. doi: 10.1016/j.ajpath.2015.11.028.

33. Pisani LF, Filippi E, Vavassori S, Munizio N, Vecchi M, Pastorelli L. Effect of proton pump inhibitors on magnesium balance: is there a link to cardiovascular risk? *Magnes Res*. 2016 Mar 1;29(1):1-10. ISSN: 0953-1424. doi: 10.1684/mrh.2016.0397.
34. Soriani P, Tontini GE, Neumann H, Ishaq S, Annunziata ML, Pastorelli L, Vecchi M. Esophageal post-inflammatory polyposis in extensive and severe Crohn's disease treated with anti-tumor necrosis factor alpha. *Endoscopy*. 2016;48 Suppl 1:E261-2. ISSN 0013-726X. doi: 10.1055/s-0042-110487.
35. Tontini GE, Wiedbrauck F, Cavallaro F, Koulaouzidis A, Marino R, Pastorelli L, Spina L, McAlindon ME, Leoni P, Vitagliano P, Cadoni S, Rondonotti E, Vecchi M. Small-bowel capsule endoscopy with panoramic view: results of the first multicenter, observational study (with videos). *Gastrointest Endosc*. 2016 Aug 8. pii: S0016-5107(16)30448-5. ISSN: 0016-5107. doi: 10.1016/j.gie.2016.07.063.
36. Caneparo V, Pastorelli L, Pisani LF, Bruni B, Prodam F, Boldorini R, Roggenbuck D, Vecchi M, Landolfo S, Gariglio M, De Andrea M. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy. *Inflamm Bowel Dis*. 2016 Dec;22(12):2977-2987. on-line ISSN 1536-4844. doi: 10.1097/MIB.0000000000000926.
37. Soriani P, Tontini GE, Vavassori S, Neumann H, Pastorelli L, Vecchi M, Lagoussis P. Over-the-scope clipping in recurrent colonic diverticular bleeding. *Endoscopy*. 2016 0;48(S 01):E306-E307. ISSN 0013-726X. doi: 10.1055/s-0042-115942.
38. Tontini GE, Rimondi A, Neumann H, Ishaq S, Cavallaro F, Vecchi M, Pastorelli L. Usefulness of Virtual Chromoendoscopy with Optical Enhancement in everyday clinical practice. *Adv Res Gastroentero Hepatol*. 2017 7(4):ARGH.MS.ID.555719
39. Marinoni B, Pastorelli L, Neumann H, Ishaq S, Cavallaro F, Spina L, Vecchi M, Tontini GE. Oozing papilloma over an esophageal varix: First report of endoscopic band ligation treatment. *Adv Res Gastroentero Hepatol*. 2017 7(4):ARGH.MS.ID.555720
40. Tontini GE, Neumann H, Pastorelli L, Spina L, Cavallaro F, Soriani P, Rimondi A, Bruni B, Clemente C, Fagnani F, Lagoussis P, Carmignani L, Vecchi M. Thulium laser in interventional endoscopy: animal and human studies. *Endoscopy*. 2017 Jan 20. ISSN 0013-726X. doi: 10.1055/s-0042-122014.
41. Cavallaro F, Duca L, Pisani LF, Rigolini R, Spina L, Tontini GE, Munizio N, Costa E, Cappellini MD, Vecchi M, Pastorelli L. Anti-TNF-Mediated Modulation of Prohepcidin Improves Iron Availability in Inflammatory Bowel Disease, in an IL-6-Mediated Fashion. *Can J Gastroenterol Hepatol*. 2017;2017:6843976. ISSN: 2291-2789. doi: 10.1155/2017/6843976.
42. Tontini GE, Rath T, Pastorelli L, Vecchi M, Neumann H. Surveillance strategies for colitis-associated cancer: state of the art and future perspectives. *Expert Rev Gastroenterol Hepatol*. 2017 Mar 1:1-11. ISSN: 1747-4124 doi: 10.1080/17474124.2017.1297705.
43. Pastorelli L, Pizarro TT. Interleukin-37: A Peacekeeper at the Intestinal Borders. *Dig Dis Sci*. 2017 May;62(5):1103-1106. doi: 10.1007/s10620-017-4523-0.
44. Pisani LF, Tontini GE, Marinoni B, Villanacci V, Bruni B, Vecchi M, Pastorelli L. Biomarkers and Microscopic Colitis: An Unmet Need in Clinical Practice. *Front Med (Lausanne)*. 2017 May 10;4:54. doi: 10.3389/fmed.2017.00054.
45. Tontini GE, Neumann H, Rimondi A, Vavassori S, Bruni B, Cattignoli G, Zhou PH, Pastorelli L, Vecchi M. Ex vivo experimental study on the Thulium laser system: new horizons for interventional endoscopy (with videos). *Endosc Int Open*. 2017 Jun;5(6):E410-E415. doi: 10.1055/s-0043-106738.
46. Nardelli S, Pisani LF, Tontini GE, Vecchi M, Pastorelli L. MMX® technology and its applications in gastrointestinal diseases. *Therap Adv Gastroenterol*. 2017 Jul;10(7):545-552. doi: 10.1177/1756283X17709974.
47. Toscano M, De Grandi R, Pastorelli L, Vecchi M, Drago L. A consumer's guide for probiotics: 10 golden rules for a correct use. *Dig Liver Dis*. 2017 Nov;49(11):1177-1184. doi: 10.1016/j.dld.2017.07.011.
48. Moriggi M, Pastorelli L, Torretta E, Tontini GE, Capitanio D, Bogetto SF, Vecchi M, Gelfi C. Contribution of Extracellular Matrix and Signal Mechanotransduction to Epithelial Cell Damage in Inflammatory Bowel Disease Patients: A Proteomic Study. *Proteomics*. 2017 Oct 13. doi: 10.1002/pmic.201700164.
49. Pescatori LC, Mauri G, Savarino E, Pastorelli L, Vecchi M, Sconfienza LM. Bowel Sonoelastography in Patients with Crohn's Disease: A Systematic Review. *Ultrasound Med Biol*. 2017 Nov 28. pii: S0301-5629(17)32401-8. doi: 10.1016/j.ultrasmedbio.2017.10.004.
50. Soriani P, Tontini GE, Neumann H, de Nucci G, De Toma D, Bruni B, Vavassori S, Pastorelli L, Vecchi M, Lagoussis P. Endoscopic full-thickness resection for T1 early rectal cancer: a case series and video report. *Endosc Int Open*. 2017 Nov;5(11):E1081-E1086. doi: 10.1055/s-0043-118657.

51. Demma AV, Sartor F, Tontini GE, Pastorelli L, Vecchi M. Rheological characterization of two different suspension formulations of beclomethasone dipropionate enemas for rectal administration. *J Pharm Technol Drug Res.* 2018; 7:1. <http://dx.doi.org/10.7243/2050-120X-7-1>.
52. Lopetuso LR, De Salvo C, Pastorelli L, Rana N, Senkfor HN, Petito V, Di Martino L, Scaldaferrri F, Gasbarrini A, Cominelli F, Abbott DW, Goodman WA, Pizarro TT. IL-33 promotes recovery from acute colitis by inducing miR-320 to stimulate epithelial restitution and repair. *Proc Natl Acad Sci U S A.* 2018 Sep 17. pii: 201803613. doi: 10.1073/pnas.1803613115.
53. Pastorelli L, Scaldaferrri F. Editorial: Intestinal Inflammation. *Front Med (Lausanne).* 2018 Nov 13;5:318. doi: 10.3389/fmed.2018.00318. eCollection 2018.

Contributor in:

1. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, Scribano ML, Armuzzi A, Caprioli F, Stumliolo GC, Rogai F, Vecchi M, Atreya R, Bossa F, Onali S, Fichera M, Corazza GR, Biancone L, Savarino V, Pica R, Orlando A, Pallone F, Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. *N Engl J Med.* 2015 Mar 19;372(12):1104-13. ISSN: 0028-4793. doi: 10.1056/NEJMoa1407250.
2. Biancone L, Annese V, Ardizzone S, Armuzzi A, Calabrese E, Caprioli F, Castiglione F, Comberlato M, Cottone M, Danese S, Daperno M, D'Inca R, Frieri G, Fries W, Gionchetti P, Kohn A, Latella G, Milla M, Orlando A, Papi C, Petruzzello C, Riegler G, Rizzello F, Saibeni S, Scribano ML, Vecchi M, Vernia P, Meucci G, Rugge M. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis.* 2017 Apr;49(4):338-358. doi: 10.1016/j.dld.2017.01.141.

July 4th, 2019

Luca Pastorelli